<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT04460313</url>
  </required_header>
  <id_info>
    <org_study_id>ACT0806</org_study_id>
    <nct_id>NCT04460313</nct_id>
  </id_info>
  <brief_title>Nasopharyngeal Carriage of S. Pneumoniae</brief_title>
  <official_title>Observatory of Nasopharyngeal Carriage of Streptococcus Pneumoniae (Sp) in Infants With Acute Otitis and in Healthy Child - Ancillary Study for Detection of E Coli ESBL Carriers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Association Clinique Thérapeutique Infantile du val de Marne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Association Clinique Thérapeutique Infantile du val de Marne</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This nasopharyngeal (NP) carriage surveillance study was requested by the European Agency for&#xD;
      the Evaluation of Medicinal Products as a post-licensing commitment to determine whether the&#xD;
      use of the pneumococcal conjugate vaccines (PCVs) including 7 then 13 valents (introduced in&#xD;
      2001 and 2010, respectively) caused a shift in the distribution of Streptococcus pneumoniae&#xD;
      serotypes in children with acute otitis media and modified the resistance of this bacterial&#xD;
      species to antibiotics.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Since September 2001, 121 pediatricians who are part of a research and teaching network&#xD;
      (ACTIV) throughout France participated at this prospective study. From October to June of&#xD;
      each subsequent year, children of both sexes suffering from suppurative acute otitis media&#xD;
      (AOM) with fever and/or otalgia (in order to increase the probability of pneumococcal AOM),&#xD;
      aged 6 to 24 months, were enrolled.&#xD;
&#xD;
      And a second group of healthy children aged 6 months to 15 years were also enrolled for the&#xD;
      main study.&#xD;
&#xD;
      For ancillary study a subgroup of children were enrolled for assessment of E. coli (ESBL)&#xD;
      resistance.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 11, 2001</start_date>
  <completion_date type="Anticipated">December 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>multicenter nationwide prospective cohort</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>S. Pneumoniae colonisation to detect emerging serotypes</measure>
    <time_frame>at inclusion</time_frame>
    <description>The percentage of children colonised by non vaccine serotypes -</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Detect the emergence of resistance S. pneumoniae</measure>
    <time_frame>at inclusion</time_frame>
    <description>Percentage of penicillin resistant S. pneumoniae</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the rhinopharyngeal carriage of other bacteria</measure>
    <time_frame>at inclusion</time_frame>
    <description>Haemophilus influenzae, Moraxella Catarrhalis, and Staphylococcus aureus in AOM group and healthy children.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Detect the emergence of new serotypes</measure>
    <time_frame>at inclusion</time_frame>
    <description>&gt; 10 Percent of isolated Sp, 5 percent of carrier children</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For the ancillary study, the resistance of E. coli (ESBL) will be evaluated.</measure>
    <time_frame>at inclusion</time_frame>
    <description>Assessment of E. coli (ESBL) resistance.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">23560</enrollment>
  <condition>Nasopharyngeal Carriage</condition>
  <condition>Children, Only</condition>
  <condition>Antibiotic Resistant Strain</condition>
  <arm_group>
    <arm_group_label>prospective cohort</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Nasopharyngeal sample for each enrolled children</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ESBL cohort</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Stool or anorectal swab samples for a subgroup of children</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>nasopharyngeal sample</intervention_name>
    <description>Nasopharyngeal swabs from children with acute otitis media aged 6 to 24 months. The swabs were analyzed by the French National Reference Centre for Pneumococci.</description>
    <arm_group_label>ESBL cohort</arm_group_label>
    <arm_group_label>prospective cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Stools collection or anorectal swab samples</intervention_name>
    <description>For a subgroup of children stools samples or anorectal swab samples were collected for assessment of E. coli (ESBL) resistance</description>
    <arm_group_label>ESBL cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  both sexes&#xD;
&#xD;
          -  suffering from suppurative AOM&#xD;
&#xD;
          -  age: 6 months to 24 months for AOM&#xD;
&#xD;
          -  age: 6 months to 15 years for healthy children&#xD;
&#xD;
          -  informed consent from parents or guardians&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Children with antibiotic treatment within 7 days before enrolment,&#xD;
&#xD;
          -  severe underlying disease,&#xD;
&#xD;
          -  inclusion in the study during the previous 12 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Cohen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Association Clinique Thérapeutique Infantile du val de Marne</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Corinne Levy, MD</last_name>
    <phone>0033148850404</phone>
    <email>corinne.levy@activ-france.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stéphane Béchet, MsC</last_name>
    <phone>0033148850404</phone>
    <email>stephane.bechet@activ-france.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>ACTIV</name>
      <address>
        <city>Créteil</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Corinne Levy, MD</last_name>
      <phone>0033148850404</phone>
      <email>corinne.levy@activ-france.fr</email>
    </contact>
    <contact_backup>
      <last_name>Stéphane Béchet, MSc</last_name>
      <phone>0033148850404</phone>
      <email>stephane.bechet@activ-france.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>https://www.activ-france.com/fr/publications</url>
    <description>ACTIV publications</description>
  </link>
  <results_reference>
    <citation>Ouldali N, Cohen R, Levy C, Gelbert-Baudino N, Seror E, Corrard F, Vie Le Sage F, Michot AS, Romain O, Bechet S, Bonacorsi S, Angoulvant F, Varon E. Pneumococcal susceptibility to antibiotics in carriage: a 17 year time series analysis of the adaptive evolution of non-vaccine emerging serotypes to a new selective pressure environment. J Antimicrob Chemother. 2019 Oct 1;74(10):3077-3086. doi: 10.1093/jac/dkz281.</citation>
    <PMID>31280295</PMID>
  </results_reference>
  <results_reference>
    <citation>Rybak A, Levy C, Bonacorsi S, Bechet S, Vie le Sage F, Elbez A, Varon E, Cohen R. Antibiotic Resistance of Potential Otopathogens Isolated From Nasopharyngeal Flora of Children With Acute Otitis Media Before, During and After Pneumococcal Conjugate Vaccines Implementation. Pediatr Infect Dis J. 2018 Mar;37(3):e72-e78. doi: 10.1097/INF.0000000000001862.</citation>
    <PMID>29227464</PMID>
  </results_reference>
  <results_reference>
    <citation>Birgy A, Bidet P, Levy C, Sobral E, Cohen R, Bonacorsi S. CTX-M-27-Producing Escherichia coli of Sequence Type 131 and Clade C1-M27, France. Emerg Infect Dis. 2017 May;23(5):885. doi: 10.3201/eid2305.161865. No abstract available.</citation>
    <PMID>28418829</PMID>
  </results_reference>
  <results_reference>
    <citation>Cohen R, Varon E, Doit C, Schlemmer C, Romain O, Thollot F, Bechet S, Bonacorsi S, Levy C. A 13-year survey of pneumococcal nasopharyngeal carriage in children with acute otitis media following PCV7 and PCV13 implementation. Vaccine. 2015 Sep 22;33(39):5118-26. doi: 10.1016/j.vaccine.2015.08.010. Epub 2015 Aug 11.</citation>
    <PMID>26271823</PMID>
  </results_reference>
  <results_reference>
    <citation>Cohen R, Levy C, Bonnet E, Thollot F, Boucherat M, Fritzell B, Derkx V, Bingen E, Varon E. Risk factors for serotype 19A carriage after introduction of 7-valent pneumococcal vaccination. BMC Infect Dis. 2011 Apr 18;11:95. doi: 10.1186/1471-2334-11-95.</citation>
    <PMID>21501471</PMID>
  </results_reference>
  <results_reference>
    <citation>Cohen R, Bingen E, Levy C, Thollot F, Boucherat M, Derkx V, Varon E. Nasopharyngeal flora in children with acute otitis media before and after implementation of 7 valent pneumococcal conjugate vaccine in France. BMC Infect Dis. 2012 Mar 7;12:52. doi: 10.1186/1471-2334-12-52.</citation>
    <PMID>22397629</PMID>
  </results_reference>
  <results_reference>
    <citation>Levy C, Vie le Sage F, Varon E, Chalumeau M, Grimprel E, Cohen R. Pediatric Ambulatory and Hospital Networks for Surveillance and Clinical Epidemiology of Community-Acquired Infections. J Pediatr. 2018 Mar;194:269-270.e2. doi: 10.1016/j.jpeds.2017.11.050. Epub 2018 Feb 22. No abstract available.</citation>
    <PMID>29637893</PMID>
  </results_reference>
  <results_reference>
    <citation>Vermee Q, Cohen R, Hays C, Varon E, Bonacorsi S, Bechet S, Thollot F, Corrard F, Poyart C, Levy C, Raymond J. Biofilm production by Haemophilus influenzae and Streptococcus pneumoniae isolated from the nasopharynx of children with acute otitis media. BMC Infect Dis. 2019 Jan 11;19(1):44. doi: 10.1186/s12879-018-3657-9.</citation>
    <PMID>30634919</PMID>
  </results_reference>
  <results_reference>
    <citation>Birgy A, Madhi F, Jung C, Levy C, Cointe A, Bidet P, Hobson CA, Bechet S, Sobral E, Vuthien H, Ferroni A, Aberrane S, Cuzon G, Beraud L, Gajdos V, Launay E, Pinquier D, Haas H, Desmarest M, Dommergues MA, Cohen R, Bonacorsi S; Group of the National Observatory of Urinary tract Infection due to ESBL-producing Enterobacteriaceae in children. Diversity and trends in population structure of ESBL-producing Enterobacteriaceae in febrile urinary tract infections in children in France from 2014 to 2017. J Antimicrob Chemother. 2020 Jan 1;75(1):96-105. doi: 10.1093/jac/dkz423.</citation>
    <PMID>31617912</PMID>
  </results_reference>
  <results_reference>
    <citation>Mizrahi A, Cohen R, Varon E, Bonacorsi S, Bechet S, Poyart C, Levy C, Raymond J. Non typable-Haemophilus influenzae biofilm formation and acute otitis media. BMC Infect Dis. 2014 Jul 19;14:400. doi: 10.1186/1471-2334-14-400.</citation>
    <PMID>25037572</PMID>
  </results_reference>
  <results_reference>
    <citation>Birgy A, Levy C, Bidet P, Thollot F, Derkx V, Bechet S, Mariani-Kurkdjian P, Cohen R, Bonacorsi S. ESBL-producing Escherichia coli ST131 versus non-ST131: evolution and risk factors of carriage among French children in the community between 2010 and 2015. J Antimicrob Chemother. 2016 Oct;71(10):2949-56. doi: 10.1093/jac/dkw219. Epub 2016 Jun 20.</citation>
    <PMID>27330068</PMID>
  </results_reference>
  <results_reference>
    <citation>Hau I, Levy C, Caeymaex L, Cohen R. Impact of pneumococcal conjugate vaccines on microbial epidemiology and clinical outcomes of acute otitis media. Paediatr Drugs. 2014 Feb;16(1):1-12. doi: 10.1007/s40272-013-0044-2.</citation>
    <PMID>23963858</PMID>
  </results_reference>
  <results_reference>
    <citation>Birgy A, Cohen R, Levy C, Bidet P, Courroux C, Benani M, Thollot F, Bingen E. Community faecal carriage of extended-spectrum beta-lactamase-producing Enterobacteriaceae in French children. BMC Infect Dis. 2012 Nov 21;12:315. doi: 10.1186/1471-2334-12-315.</citation>
    <PMID>23171127</PMID>
  </results_reference>
  <results_reference>
    <citation>Caeymaex L, Varon E, Levy C, Bechet S, Derkx V, Desvignes V, Doit C, Cohen R. Characteristics and outcomes of acute otitis media in children carrying streptococcus pneumoniae or haemophilus influenzae in their nasopharynx as a single otopathogen after introduction of the heptavalent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2014 May;33(5):533-6. doi: 10.1097/INF.0000000000000213.</citation>
    <PMID>24263220</PMID>
  </results_reference>
  <results_reference>
    <citation>Cohen R, Levy C, Bingen E, Koskas M, Nave I, Varon E. Impact of 13-valent pneumococcal conjugate vaccine on pneumococcal nasopharyngeal carriage in children with acute otitis media. Pediatr Infect Dis J. 2012 Mar;31(3):297-301. doi: 10.1097/INF.0b013e318247ef84.</citation>
    <PMID>22330166</PMID>
  </results_reference>
  <results_reference>
    <citation>Cohen R, Levy C, Bingen E, Bechet S, Derkx V, Werner A, Koskas M, Varon E. [Nasopharyngeal carriage of children 6 to 60 months during the implementation of the 13-valent pneumococcal conjugate vaccine]. Arch Pediatr. 2012 Oct;19(10):1132-9. doi: 10.1016/j.arcped.2012.07.013. Epub 2012 Aug 24. French.</citation>
    <PMID>22925540</PMID>
  </results_reference>
  <results_reference>
    <citation>Cohen R, Levy C, Thollot F, de La Rocque F, Koskas M, Bonnet E, Fritzell B, Varon E. Pneumococcal conjugate vaccine does not influence Staphylococcus aureus carriage in young children with acute otitis media. Clin Infect Dis. 2007 Dec 15;45(12):1583-7. doi: 10.1086/523734. Erratum In: Clin Infect Dis. 2008 Feb 1;46(3):489.</citation>
    <PMID>18190319</PMID>
  </results_reference>
  <results_reference>
    <citation>Cohen R, Levy C, de La Rocque F, Gelbert N, Wollner A, Fritzell B, Bonnet E, Tetelboum R, Varon E. Impact of pneumococcal conjugate vaccine and of reduction of antibiotic use on nasopharyngeal carriage of nonsusceptible pneumococci in children with acute otitis media. Pediatr Infect Dis J. 2006 Nov;25(11):1001-7. doi: 10.1097/01.inf.0000243163.85163.a8.</citation>
    <PMID>17072121</PMID>
  </results_reference>
  <verification_date>December 2022</verification_date>
  <study_first_submitted>June 19, 2020</study_first_submitted>
  <study_first_submitted_qc>July 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 7, 2020</study_first_posted>
  <last_update_submitted>December 22, 2022</last_update_submitted>
  <last_update_submitted_qc>December 22, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">December 27, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pneumococcal conjugate vaccine</keyword>
  <keyword>Streptococcus pneumoniae</keyword>
  <keyword>Carriage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT04460313
org study id: ACT0806
nct id: NCT04460313
lead sponsor: 
collaborator: 
has dmc: Yes
is fda regulated drug: No
is fda regulated device: No
This nasopharyngeal (NP) carriage surveillance study was requested by the European Agency for
      the Evaluation of Medicinal Products as a post-licensing commitment to determine whether the
      use of the pneumococcal conjugate vaccines (PCVs) including 7 then 13 valents (introduced in
      2001 and 2010, respectively) caused a shift in the distribution of Streptococcus pneumoniae
      serotypes in children with acute otitis media and modified the resistance of this bacterial
      species to antibiotics.
Since September 2001, 121 pediatricians who are part of a research and teaching network
      (ACTIV) throughout France participated at this prospective study. From October to June of
      each subsequent year, children of both sexes suffering from suppurative acute otitis media
      (AOM) with fever and/or otalgia (in order to increase the probability of pneumococcal AOM),
      aged 6 to 24 months, were enrolled.

      And a second group of healthy children aged 6 months to 15 years were also enrolled for the
      main study.

      For ancillary study a subgroup of children were enrolled for assessment of E. coli (ESBL)
      resistance.
allocation: Non-Randomized
intervention model: Single Group Assignment
intervention model description: multicenter nationwide prospective cohort
primary purpose: Other
masking: None (Open Label)
measure: S. Pneumoniae colonisation to detect emerging serotypes
time frame: at inclusion
description: The percentage of children colonised by non vaccine serotypes -
measure: Detect the emergence of resistance S. pneumoniae
time frame: at inclusion
description: Percentage of penicillin resistant S. pneumoniae
measure: Evaluation of the rhinopharyngeal carriage of other bacteria
time frame: at inclusion
description: Haemophilus influenzae, Moraxella Catarrhalis, and Staphylococcus aureus in AOM group and healthy children.
measure: Detect the emergence of new serotypes
time frame: at inclusion
description: > 10 Percent of isolated Sp, 5 percent of carrier children
measure: For the ancillary study, the resistance of E. coli (ESBL) will be evaluated.
time frame: at inclusion
description: Assessment of E. coli (ESBL) resistance.
arm group label: prospective cohort
arm group type: Other
description: Nasopharyngeal sample for each enrolled children
arm group label: ESBL cohort
arm group type: Other
description: Stool or anorectal swab samples for a subgroup of children
intervention type: Other
intervention name: nasopharyngeal sample
description: Nasopharyngeal swabs from children with acute otitis media aged 6 to 24 months. The swabs were analyzed by the French National Reference Centre for Pneumococci.
arm group label: ESBL cohort
arm group label: prospective cohort
intervention type: Other
intervention name: Stools collection or anorectal swab samples
description: For a subgroup of children stools samples or anorectal swab samples were collected for assessment of E. coli (ESBL) resistance
arm group label: ESBL cohort
criteria: 
gender: All
minimum age: 6 Months
maximum age: 15 Years
healthy volunteers: Accepts Healthy Volunteers
last name: Robert Cohen, MD
role: Principal Investigator
affiliation: Association Clinique Thérapeutique Infantile du val de Marne
last name: Corinne Levy, MD
phone: 0033148850404
email: corinne.levy@activ-france.fr
last name: Stéphane Béchet, MsC
phone: 0033148850404
email: stephane.bechet@activ-france.fr
facility: 
status: Recruiting
contact: 
contact backup: 
country: France
url: https://www.activ-france.com/fr/publications
description: ACTIV publications
citation: Ouldali N, Cohen R, Levy C, Gelbert-Baudino N, Seror E, Corrard F, Vie Le Sage F, Michot AS, Romain O, Bechet S, Bonacorsi S, Angoulvant F, Varon E. Pneumococcal susceptibility to antibiotics in carriage: a 17 year time series analysis of the adaptive evolution of non-vaccine emerging serotypes to a new selective pressure environment. J Antimicrob Chemother. 2019 Oct 1;74(10):3077-3086. doi: 10.1093/jac/dkz281.
PMID: 31280295
citation: Rybak A, Levy C, Bonacorsi S, Bechet S, Vie le Sage F, Elbez A, Varon E, Cohen R. Antibiotic Resistance of Potential Otopathogens Isolated From Nasopharyngeal Flora of Children With Acute Otitis Media Before, During and After Pneumococcal Conjugate Vaccines Implementation. Pediatr Infect Dis J. 2018 Mar;37(3):e72-e78. doi: 10.1097/INF.0000000000001862.
PMID: 29227464
citation: Birgy A, Bidet P, Levy C, Sobral E, Cohen R, Bonacorsi S. CTX-M-27-Producing Escherichia coli of Sequence Type 131 and Clade C1-M27, France. Emerg Infect Dis. 2017 May;23(5):885. doi: 10.3201/eid2305.161865. No abstract available.
PMID: 28418829
citation: Cohen R, Varon E, Doit C, Schlemmer C, Romain O, Thollot F, Bechet S, Bonacorsi S, Levy C. A 13-year survey of pneumococcal nasopharyngeal carriage in children with acute otitis media following PCV7 and PCV13 implementation. Vaccine. 2015 Sep 22;33(39):5118-26. doi: 10.1016/j.vaccine.2015.08.010. Epub 2015 Aug 11.
PMID: 26271823
citation: Cohen R, Levy C, Bonnet E, Thollot F, Boucherat M, Fritzell B, Derkx V, Bingen E, Varon E. Risk factors for serotype 19A carriage after introduction of 7-valent pneumococcal vaccination. BMC Infect Dis. 2011 Apr 18;11:95. doi: 10.1186/1471-2334-11-95.
PMID: 21501471
citation: Cohen R, Bingen E, Levy C, Thollot F, Boucherat M, Derkx V, Varon E. Nasopharyngeal flora in children with acute otitis media before and after implementation of 7 valent pneumococcal conjugate vaccine in France. BMC Infect Dis. 2012 Mar 7;12:52. doi: 10.1186/1471-2334-12-52.
PMID: 22397629
citation: Levy C, Vie le Sage F, Varon E, Chalumeau M, Grimprel E, Cohen R. Pediatric Ambulatory and Hospital Networks for Surveillance and Clinical Epidemiology of Community-Acquired Infections. J Pediatr. 2018 Mar;194:269-270.e2. doi: 10.1016/j.jpeds.2017.11.050. Epub 2018 Feb 22. No abstract available.
PMID: 29637893
citation: Vermee Q, Cohen R, Hays C, Varon E, Bonacorsi S, Bechet S, Thollot F, Corrard F, Poyart C, Levy C, Raymond J. Biofilm production by Haemophilus influenzae and Streptococcus pneumoniae isolated from the nasopharynx of children with acute otitis media. BMC Infect Dis. 2019 Jan 11;19(1):44. doi: 10.1186/s12879-018-3657-9.
PMID: 30634919
citation: Birgy A, Madhi F, Jung C, Levy C, Cointe A, Bidet P, Hobson CA, Bechet S, Sobral E, Vuthien H, Ferroni A, Aberrane S, Cuzon G, Beraud L, Gajdos V, Launay E, Pinquier D, Haas H, Desmarest M, Dommergues MA, Cohen R, Bonacorsi S; Group of the National Observatory of Urinary tract Infection due to ESBL-producing Enterobacteriaceae in children. Diversity and trends in population structure of ESBL-producing Enterobacteriaceae in febrile urinary tract infections in children in France from 2014 to 2017. J Antimicrob Chemother. 2020 Jan 1;75(1):96-105. doi: 10.1093/jac/dkz423.
PMID: 31617912
citation: Mizrahi A, Cohen R, Varon E, Bonacorsi S, Bechet S, Poyart C, Levy C, Raymond J. Non typable-Haemophilus influenzae biofilm formation and acute otitis media. BMC Infect Dis. 2014 Jul 19;14:400. doi: 10.1186/1471-2334-14-400.
PMID: 25037572
citation: Birgy A, Levy C, Bidet P, Thollot F, Derkx V, Bechet S, Mariani-Kurkdjian P, Cohen R, Bonacorsi S. ESBL-producing Escherichia coli ST131 versus non-ST131: evolution and risk factors of carriage among French children in the community between 2010 and 2015. J Antimicrob Chemother. 2016 Oct;71(10):2949-56. doi: 10.1093/jac/dkw219. Epub 2016 Jun 20.
PMID: 27330068
citation: Hau I, Levy C, Caeymaex L, Cohen R. Impact of pneumococcal conjugate vaccines on microbial epidemiology and clinical outcomes of acute otitis media. Paediatr Drugs. 2014 Feb;16(1):1-12. doi: 10.1007/s40272-013-0044-2.
PMID: 23963858
citation: Birgy A, Cohen R, Levy C, Bidet P, Courroux C, Benani M, Thollot F, Bingen E. Community faecal carriage of extended-spectrum beta-lactamase-producing Enterobacteriaceae in French children. BMC Infect Dis. 2012 Nov 21;12:315. doi: 10.1186/1471-2334-12-315.
PMID: 23171127
citation: Caeymaex L, Varon E, Levy C, Bechet S, Derkx V, Desvignes V, Doit C, Cohen R. Characteristics and outcomes of acute otitis media in children carrying streptococcus pneumoniae or haemophilus influenzae in their nasopharynx as a single otopathogen after introduction of the heptavalent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2014 May;33(5):533-6. doi: 10.1097/INF.0000000000000213.
PMID: 24263220
citation: Cohen R, Levy C, Bingen E, Koskas M, Nave I, Varon E. Impact of 13-valent pneumococcal conjugate vaccine on pneumococcal nasopharyngeal carriage in children with acute otitis media. Pediatr Infect Dis J. 2012 Mar;31(3):297-301. doi: 10.1097/INF.0b013e318247ef84.
PMID: 22330166
citation: Cohen R, Levy C, Bingen E, Bechet S, Derkx V, Werner A, Koskas M, Varon E. [Nasopharyngeal carriage of children 6 to 60 months during the implementation of the 13-valent pneumococcal conjugate vaccine]. Arch Pediatr. 2012 Oct;19(10):1132-9. doi: 10.1016/j.arcped.2012.07.013. Epub 2012 Aug 24. French.
PMID: 22925540
citation: Cohen R, Levy C, Thollot F, de La Rocque F, Koskas M, Bonnet E, Fritzell B, Varon E. Pneumococcal conjugate vaccine does not influence Staphylococcus aureus carriage in young children with acute otitis media. Clin Infect Dis. 2007 Dec 15;45(12):1583-7. doi: 10.1086/523734. Erratum In: Clin Infect Dis. 2008 Feb 1;46(3):489.
PMID: 18190319
citation: Cohen R, Levy C, de La Rocque F, Gelbert N, Wollner A, Fritzell B, Bonnet E, Tetelboum R, Varon E. Impact of pneumococcal conjugate vaccine and of reduction of antibiotic use on nasopharyngeal carriage of nonsusceptible pneumococci in children with acute otitis media. Pediatr Infect Dis J. 2006 Nov;25(11):1001-7. doi: 10.1097/01.inf.0000243163.85163.a8.
PMID: 17072121
responsible party type: Sponsor
mesh term: Pneumonia
sharing ipd: No